An Inactivated Cell-Culture Vaccine against Yellow FeverArchived

ECDC comment-16 May 2011

A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.

As of 2 February 2017, 826 cases (including 155 confirmed) have been reported in Brazil. This represents an increase of 315 cases (including 67 confirmed) since the last CDTR. The most-affected state remains Minas Gerais, with 740 cases (including 138 confirmed) reported.

As of 2 February 2017, 826 cases (including 155 confirmed) have been reported in Brazil. This represents an increase of 315 cases (including 67 confirmed) since the last CDTR. The most-affected state remains Minas Gerais, with 740 cases (including 138 confirmed) reported.

Epidemiological update: Yellow fever outbreak in Brazil, 9 March 2017

Epidemiological update-9 Mar 2017

​As of 6 March 2017, Brazil has reported 1 337 cases of yellow fever (966 suspected and 371 confirmed), including 233 deaths (106 suspected and 127 confirmed), in seven states. The case-fatality rate is 17.4% among all cases and 34.2% among confirmed cases.

​Between 6 January and 16 March 2017, Brazil has reported 1 357 cases (933 suspected and 424 confirmed), including 249 deaths (112 suspected and 137 confirmed). The case-fatality rate is 18.3% among all cases and 32.3% among confirmed cases.

​Between 6 January and 16 March 2017, Brazil has reported 1 357 cases (933 suspected and 424 confirmed), including 249 deaths (112 suspected and 137 confirmed). The case-fatality rate is 18.3% among all cases and 32.3% among confirmed cases.